Efficacy of Durvalumab for Early-Stage TNBC Examined by Race
FRIDAY, Aug. 19, 2022 -- Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for African American (AA)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 19, 2022 Category: Pharmaceuticals Source Type: news
AstraZeneca India receives DCGI's nod to market drug treating breast cancer
The Drugs Controller General of India (DCGI) has approved Lynparza (Olaparib) as a monotherapy for the treatment of adult patients with early breast cancer, who have previously been treated with neoadjuvant or adjuvant chemotherapy. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 19, 2022 Category: Pharmaceuticals Source Type: news
Survival Boost With Neoadjuvant Chemo-Immunotherapy in NSCLC Survival Boost With Neoadjuvant Chemo-Immunotherapy in NSCLC
Adding neoadjuvant nivolumab to chemotherapy in stage IIIA/IIIB non ¬–small cell lung cancer markedly improves both progression-free and overall survival over neoadjuvant chemotherapy alone.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 10, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Neodjuvant Chemoimmunotherapy Takes Another Step Forward in Stage IIIA-B NSCLC
(MedPage Today) -- VIENNA -- The addition of neoadjuvant nivolumab (Opdivo) to chemotherapy significantly improved outcomes in patients with resectable stage IIIA-B non-small cell lung cancer, according to results from the NADIM II trial.
The... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 9, 2022 Category: Hematology Source Type: news
Treatment of Early Non-Small Cell Lung Cancer: A New Vigilance for Neoadjuvant Therapy Treatment of Early Non-Small Cell Lung Cancer: A New Vigilance for Neoadjuvant Therapy
Jeffrey Thiboutot, MD, MHS, considers the diagnostic implications of neoadjuvant therapy of early non-small cell lung cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 9, 2022 Category: Consumer Health News Tags: None MDAngle Source Type: news
Neoadjuvant mFOLFIRINOX Studied for Borderline Resectable PDAC
WEDNESDAY, Aug. 3, 2022 -- For patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC), favorable overall survival was observed following treatment with eight cycles of neoadjuvant modified FOLFIRINOX (mFOLFIRINOX), according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 3, 2022 Category: Pharmaceuticals Source Type: news
Albumin-Bound Paclitaxel Plus Carboplatin for Lung SCC Albumin-Bound Paclitaxel Plus Carboplatin for Lung SCC
Is this regimen a safe and effective option for the neoadjuvant treatment of potentially resectable lung squamous cell carcinoma?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 1, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Cancer Tx Eye Toxicity; ASCO Targets Preauthorization; Liver Transplant for Seniors
(MedPage Today) --
Neoadjuvant immunotherapy for aggressive breast cancer benefited all patients, regardless of race. (American Association for Cancer Research)
Treatments for genitourinary cancers have a risk of a wide range of ophthalmologic... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 29, 2022 Category: Hematology Source Type: news
MARF to Host International Symposium on Malignant Mesothelioma
Leading medical specialists will gather with mesothelioma patients, families, friends and advocates at the much-anticipated 2022 International Symposium on Malignant Mesothelioma, July 23, in Chicago. This is an event well worth attending.
The day-long symposium will be held at Summit Chicago, a welcoming venue where a wide range of mesothelioma experts will be speaking on related topics and mixing with all those who attend.
This is the first in-person gathering for the annual event since 2019 because of the COVID-19 pandemic. Much of the symposium will be available for viewing virtually, free of charge, for those un...
Source: Asbestos and Mesothelioma News - July 20, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Awareness/Advocacy Mesothelioma Peritoneal Pleural Treatment Source Type: news
What's the Safest Path to Neoadjuvant Therapy in Liver Cancer?
(MedPage Today) -- Immune checkpoint inhibitors (ICIs) had a more favorable safety profile for advanced liver cancer than did tyrosine kinase inhibitors (TKIs), according to a clinical trial meta-analysis.
In a pooled analysis of 30 studies, ICIs... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - July 18, 2022 Category: Gastroenterology Source Type: news
COMMENTARY: Adjuvant vs Neoadjuvant for Resectable NSCLC? COMMENTARY: Adjuvant vs Neoadjuvant for Resectable NSCLC?
Which is better? Concurrent neoadjuvant chemotherapy and immunotherapy or concurrent adjuvant chemotherapy with immunotherapy for non –small cell lung cancer (NSCLC)?Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 15, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Immunotherapy Charts New Course for Resectable NSCLC Treatment Immunotherapy Charts New Course for Resectable NSCLC Treatment
Three cycles of neoadjuvant nivolumab plus chemotherapy improved long-term clinical outcomes in patients with resectable stage IB-IIIA NSCLC.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Investor Update - June 9, 2022 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news
Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
